Aardvark Therapeutics (AARD) Corporate Presentation summary

Strategic positioning and growth outlook

• Focus on suppressing hunger to treat rare metabolic diseases and obesity, targeting root causes with oral drugs.

• Phase 3 HERO trial topline data expected in Q3 2026, with funding secured into 2027.

• Addressing severe unmet needs in Prader-Willi Syndrome (PWS) and obesity, aiming to overcome limitations of current therapies.

Leadership and expertise

• Leadership team spans clinical, scientific, and commercial domains, including experienced executives and board members from biotech and venture capital.

Scientific innovation and clinical pipeline

• Distinct neural pathways for hunger and appetite are targeted, with ARD-101 acting on gut-localized hormone secretion to address hyperphagia in PWS.

• ARD-101 demonstrated hunger reduction and favorable safety in Phase 2 PWS trials; Phase 3 HERO trial is ongoing with a 12-week treatment period.

• ARD-201, a fixed-dose combination, is being developed for obesity, showing significant weight loss and prevention of weight regain in preclinical models.